Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06369571
Other study ID # IRB00439268
Secondary ID
Status Not yet recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date July 2024
Est. completion date December 2027

Study information

Verified date April 2024
Source Johns Hopkins University
Contact Tanya J McDonald, MD, PhD
Phone 4105022227
Email twill145@jhmi.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Ketogenic diet therapies (KDTs) emphasize high fat and very low carbohydrate intake and help to control seizures in adults who fail to respond to medications. However, KDT use can lead to increased cholesterol levels in some adults with epilepsy (AWE). Treatments that can reverse elevations in cholesterol observed with long-term KDT use without compromising diet adherence and seizure control are needed. The proposed study will explore the feasibility and safety of diet modification and statin use to lower cholesterol in this population. Study findings will help guide doctors utilizing KDTs in adults with epilepsy on how to approach managing elevations in cholesterol.


Description:

The scientific premise of this proposal is that established or long-term (≥ 12 months) Modified Atkins diet (MAD) use in AWE influences atherosclerotic cardiovascular disease (ASCVD) risk and can be modified to reduce dyslipidemia when observed. Hence, the overarching goals of this proposal are to explore the safety and feasibility of dyslipidemia management strategies to reduce ASCVD risk in AWE on MAD without increasing seizure risk. This study will collect data before and after randomly assigned interventions to reduce LDL in AWE on long-term MAD recruited from patients receiving clinical care in the Johns Hopkins Adult Epilepsy Diet Center. AWE with dyslipidemia on long-term MAD will be randomized 1:1 to either MAD modification (10% reduction of dietary energy from saturated fat, replaced with poly-unsaturated fat ) or moderate-intensity statin use (atorvastatin 10mg) for 12 weeks.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 22
Est. completion date December 2027
Est. primary completion date January 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Modified Atkins Diet use = 12 months 2. Dyslipidemia based on American College of Cardiology/American Heart Association guidelines (i.e., LDL =190 mg/dL, 10-year ASCVD risk =5% with risk enhancers, etc.) 3. 18 years of age or older 4. Body mass index (BMI) > 18.5 5. Stable anti-seizure medication regimen for > 1 month. Exclusion Criteria: 1. < 18 years of age 2. Body mass index (BMI) < 18.5 3. Changes in anti-seizure medication regimen < 1 month prior to participation 4. Known ASCVD (history of acute coronary syndrome, myocardial infarction, angina, stroke, transient ischemic attack, or peripheral artery disease) 5. Current statin medication use 6. Prior serious adverse response to atorvastatin or other statin medications 7. Uncorrected carnitine deficiency 8. Pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Atorvastatin 10mg
Atorvastatin 10mg daily by mouth
Other:
Modification of dietary fat composition
Replace 10% of saturated fat intake with polyunsaturated fat

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Johns Hopkins University American Heart Association

Outcome

Type Measure Description Time frame Safety issue
Primary Diet adherence as assessed by 3 day food records Diet adherence will be based on the ability to achieve 10% reduction in dietary energy from saturated fat assessed from 3-day food records, the gold standard for diet intake assessments. 12 weeks
Primary Statin Adherence Statin adherence will be determined based on pills returned at study completion, with participants labeled adherent if 80% or more of pills were consumed. 12 weeks
Primary LDL Change 12-week % LDL change from baseline within arms and between arms 12 weeks
Primary Change in weekly seizure frequency 12-week difference in weekly seizure frequency from baseline 12 weeks
Primary Seizure severity questionnaire score 12-week difference in seizure severity questionnaire (SSQ) score (score 1-7, with higher score indicating more severe seizures) 12 weeks
Secondary Frequency of adverse events Frequency of adverse events 12 weeks
Secondary Blood ketone change 12-week difference in serum beta-hydroxybutyrate level from baseline 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT04595513 - Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants Phase 1/Phase 2
Completed NCT02909387 - Adapting Project UPLIFT for Blacks in Georgia N/A
Completed NCT05552924 - Self Acupressure on Fatigue and Sleep Quality in Epilepsy Patients N/A
Terminated NCT01668654 - Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS Phase 3
Not yet recruiting NCT05068323 - Impact of Interictal Epileptiform Activity on Some Cognitive Domains in Newly Diagnosed Epileptic Patients N/A
Completed NCT03994718 - Creative Arts II Study N/A
Recruiting NCT04076449 - Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
Completed NCT00782249 - Trial Comparing Different Stimulation Paradigms in Patients Treated With Vagus Nerve Stimulation for Refractory Epilepsy N/A
Completed NCT03683381 - App-based Intervention for Treating Insomnia Among Patients With Epilepsy N/A
Recruiting NCT05101161 - Neurofeedback Using Implanted Deep Brain Stimulation Electrodes N/A
Active, not recruiting NCT06034353 - Impact of Pharmacist-led Cognitive Behavioral Intervention on Adherence and Quality of Life of Epileptic Patients N/A
Recruiting NCT05769933 - Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
Not yet recruiting NCT06408428 - Glioma Intraoperative MicroElectroCorticoGraphy N/A
Not yet recruiting NCT05559060 - Comorbidities of Epilepsy(Cognitive and Psychiatric Dysfunction)
Completed NCT02977208 - Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use Phase 4
Completed NCT02646631 - Behavioral and Educational Tools to Improve Epilepsy Care N/A
Completed NCT02952456 - Phenomenological Approach of Epilepsy in Patients With Epilepsy
Recruiting NCT02539134 - TAK-935 Multiple Rising Dose Study in Healthy Participants Phase 1
Terminated NCT02757547 - Transcranial Magnetic Stimulation for Epilepsy N/A
Completed NCT02491073 - Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL) N/A